A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Ramucirumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 30 May 2019 Planned End Date changed from 31 Dec 2021 to 30 Nov 2021.
- 30 May 2019 Planned primary completion date changed from 31 Dec 2021 to 30 Nov 2021.
- 30 May 2019 Status changed from not yet recruiting to recruiting.